ID: ALA305377

Max Phase: Preclinical

Molecular Formula: C24H44N5O5P

Molecular Weight: 513.62

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)CCCCCOP(=O)(COCCn1cnc2c(O)nc(N)nc21)OCCCCCC(C)C

Standard InChI:  InChI=1S/C24H44N5O5P/c1-19(2)11-7-5-9-14-33-35(31,34-15-10-6-8-12-20(3)4)18-32-16-13-29-17-26-21-22(29)27-24(25)28-23(21)30/h17,19-20H,5-16,18H2,1-4H3,(H3,25,27,28,30)

Standard InChI Key:  PWCDZOMBYSFDIJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 513.62

Molecular Weight (Monoisotopic): 513.3080

AlogP: 5.75

#Rotatable Bonds: 19

Polar Surface Area: 134.61

Molecular Species: NEUTRAL

HBA: 10

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.58

CX Basic pKa: 0.89

CX LogP: 5.61

CX LogD: 5.61

Aromatic Rings: 2

Heavy Atoms: 35

QED Weighted: 0.18

Np Likeness Score: -0.29

References

1. Holý A, Günter J, Dvoráková H, Masojídková M, Andrei G, Snoeck R, Balzarini J, De Clercq E..  (1999)  Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.,  42  (12): [PMID:10377214] [10.1021/jm9811256]

Source

Source(1):

• Scientific Literature